Impact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes
Authors' conclusion
CGM use significantly increased after addition to the pharmacy benefit. Rate of change in CGM use was lower in T1DM compared to the T2DM population, but overall use remained higher among patients with T1DM.
Study context
- Population
- Insulin users with T1D or T2D, commercial insurer pharmacy and medical claims 2016–2020; policy change December 2018
- Comparison
- Continuous glucose monitoring (CGM) use before vs after expansion of CGM coverage through the pharmacy benefit
- Outcome
- Prevalence of CGM use before and after the policy change
Main finding
As reported in the abstract
Change in CGM use after policy change
Immediate change in CGM use, T1D
9.5%
P < 0.0001
Immediate change in CGM use, T2D
2.8%
P < 0.0001
Increase in rate of quarterly change, T1D
0.5%
P = 0.002
Increase in rate of quarterly change, T2D
0.8%
P < 0.0001
Further findings
CGM use · beginning of study period
CGM use · end of study period
| Outcome | T1D | T2D |
|---|---|---|
| CGM use · quarter before policy change | 30.5% | 6.6% |
Original publication
Impact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes. Diabetes Technol Ther. Published 4 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →